Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.59 |
| ▸ | FNTA | P49354 | 1/20 | 0.57 |
| ▸ | FNTB | P49356 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177261 | 0.84 | RET (0.77) | RETFNTAFNTBALDH1A1KDM4E | |
| SCHEMBL1177621 | 0.79 | FNTA (0.80) | RETFNTAFNTBALDH1A1KDM4E | |
| SCHEMBL1177028 | 0.75 | RET (0.74) | RETFNTAFNTBALDH1A1KDM4E | |
| SCHEMBL30795260 | 0.74 | RET (0.65) | RETFNTAFNTBALDH1A1KDM4E | |
| SCHEMBL2533618 | 0.74 | RET (0.65) | RETFNTAFNTBALDH1A1KDM4E | |
| SCHEMBL1177609 | 0.73 | FNTA (0.73) | RETFNTAFNTBALDH1A1KDM4E | |
| SCHEMBL15693215 | 0.73 | L3MBTL1 (0.56) | FNTAFNTBALDH1A1HSD17B10HPGD | |
| SCHEMBL15573454 | 0.72 | KDM4E (0.67) | RETFNTAFNTBALDH1A1KDM4E | |
| SCHEMBL17351499 | 0.70 | KDM4E (0.65) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| SCHEMBL1177162 | 0.70 | RET (1.00) | RETFNTAFNTBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618119-B2 | Fused cyanopyridines and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-31 | — | — | US | claimed |
| EP-2556831-A1 | 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine-6-carbonitriles as Adenosin Receptor Ligands for Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | claimed |
| EP-2556856-A1 | 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | claimed |
| EP-2234980-B1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | BAYER IP GMBH (DE) | 2013-01-23 | — | — | EP | claimed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | claimed |
| EP-2234980-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | claimed |
| WO-2009080198-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | claimed |
| US-8618119-B2 | Fused cyanopyridines and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-2556831-A1 | 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine-6-carbonitriles as Adenosin Receptor Ligands for Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2556856-A1 | 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2234980-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080198-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | TNNI3, QDPR, RYR2 | RET 4094/4885FNTA 2192/4885FNTB 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.